Login
$CSTL
$32.75 -$1.04 (3.08%) Live

$CSTL 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025

30 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Q2 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 32% over Q2 2025

29 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 28, 2026, Castle Biosciences, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following matters and cast their votes as set f...

06 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Q1 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q1 2025

26 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024

13 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million

03 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024

08 Aug 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the certificate of incorporation of the corporati...

04 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024

23 May 2025 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

ONE: He is the duly elected and acting President and Chief Executive Officer of Castle Biosciences, Inc., a Delaware corporation.

05 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024

27 Feb 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance

13 Jan 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023

04 Nov 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million

05 Aug 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million

24 May 2024 8-K: Submission of Matters to a Vote of Security Holders

On May 23, 2024, Castle Biosciences, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following matters and cast their votes as set f...

02 May 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Raising full-year 2024 revenue guidance to $255-265 million from $235-240 million

27 Mar 2024 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT CUSTOMARIL...

28 Feb 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance

08 Jan 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support